The indirect effect may result from differential expression of pro- and antiangiogenic factors, such as decreased VEGF-A or elevated TSP-1 and soluble VEGFR-1 expression, in tumor-bearing mice and cancer patients administered LDMC7,10–12. The gene discussed is FLT1; the disease is cancer.